|
Oct 1
|
3 Undervalued Small Caps In United States With Insider Buying
|
|
Sep 7
|
While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership
|
|
Aug 30
|
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
|
|
Jul 30
|
NewAmsterdam Pharma (NASDAQ:NAMS) Is In A Good Position To Deliver On Growth Plans
|
|
Jul 29
|
NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations
|
|
Jul 29
|
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
|
|
Jul 26
|
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
|
|
May 10
|
NewAmsterdam Pharma First Quarter 2024 Earnings: US$1.06 loss per share (vs US$0.50 loss in 1Q 2023)
|
|
May 9
|
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
|
|
May 3
|
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 2
|
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
|
|
Feb 14
|
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Feb 13
|
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Feb 1
|
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
|
|
Jan 1
|
Institutions own 18% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) shares but private equity firms control 52% of the company
|
|
Aug 10
|
NewAmsterdam Pharma First Half 2023 Earnings: €0.92 loss per share (vs €1.50 profit in 1H 2022)
|
|
Aug 7
|
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
|